- This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaign
- TD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment1-4
- Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the high impact the movements often have on all aspects of their lives5-7
PARSIPPANY, N.J. and TEL AVIV, Israel, Nov. 03, 2025a disease education campaign leveraging the broad recognition of football touchdowns to raise awareness and understanding of a lesser-known TD - tardive dyskinesia. The goal of the campaign is to help undiagnosed Americans living with TD, and their care partners, recognize symptoms and take action by having conversations with their healthcare provider. Terrell Davis, known for his iconic initials, "TD," and for scoring dozens of touchdowns in his career, is partnering with Teva to shine a light on 'The Other TD'.
15.4 million Americans are living with a serious mental illness,8 such as bipolar disorder, major depressive disorder, or schizophrenia, with many using antipsychotic medications to treat these conditions. While these treatments can provide much needed relief to patients, 25% of those taking certain mental health treatments may develop uncontrollable movements, known as TD.2,9,10 This disorder can make everyday tasks like eating, getting dressed, and walking difficult,1-2 but it can be treated without interrupting your mental health progress.4
"As someone who has faced my own mental health challenges, I understand the importance of speaking out and providing support for those encountering similar obstacles," said Terrell Davis, Pro Football Hall of Famer and 2x champion. "Because of this, I am honored to be partnering with Teva to use my name and platform to increase awareness around TD and empower those who might be struggling to learn more and seek treatment."
'The Other TD' provides educational information about TD, including how to recognize symptoms and its physical, emotional, social, and functional impacts. Additional resources for patients about treatment options and tips for care partners are also available.
Despite its estimated impact on 785,000 Americans, only approximately 15% receive a formal TD diagnosis and only 5% receive treatment.3 Underdiagnosis is especially high among younger individuals, men, and racial and ethnic minority groups, including Black Americans who have lower rates of formal TD diagnoses despite their TD movements being recognized an average of seven years prior.5-7 The effects of TD, however, are not solely physical. In fact, three out of four people who have TD say it severely impacts how they function, feel, and interact with others.1-3
"'The Other TD' emphasizes our commitment to TD patients seeking treatment and support, to those who may have TD but not know it, and to care partners looking to support their loved ones," said Heather DeMyers, Vice President, U.S. Innovative Medicines Marketing at Teva. "Ultimately, we want individuals to know if they are suffering from the impacts of TD-they are not alone. While TD may impact their daily life, there are effective treatment options available that don't have to interfere with their mental health journey."
Please visit TheOtherTD.comto learn more about typical TD symptoms and potential treatment options.
About Teva
Teva Pharmaceutical Industries Ltd..
About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.1,2,10
Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize products for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
References:
- Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs. Hauppauge, NY: Nova Science Publishers. 2013:235-258.
- Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov. 2013;3:1-11.7.
- Data on file. Parsippany, NJ: Teva Neuroscience, Inc.
- Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238. doi:10.2147/DDDT.S133205.
- Vando L, et al. Presented at: Neuroscience Education Institute; Nov 7 - Nov 10, 2024; Colorado Springs, CO.
- Salvaraj V, et al. Presented at: American Psychiatric Nurses' Association Annual Meeting; Oct 9 - Oct 12, 2024; Louisville, KY.
- Monroe C, et al. Presented at: American Psychiatric Nurses' Association Annual Meeting; Oct 9 - Oct 12, 2024; Louisville, KY.
- U.S. Department of Health and Human Services. (n.d.). Mental illness. National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/mental-illness (https://www.nimh.nih.gov/health/statistics/mental-illness).
- Loughlin, A. M., Lin, N., Abler, V., & Carroll, B. (2019). Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. PloS one, 14(6), e0216044, https://doi.org/10.1371/journal.pone.0216044 (https://doi.org/10.1371/journal.pone.0216044).
- Tardive dyskinesia. National Alliance on Mental Illness website. https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nami.org%2FLearn-More%2FTreatment%2FMental-Health-Medications%2FTardive-Dyskinesia&esheet=53957624&newsitemid=20240425312754&lan=en-US&anchor=https%3A%2F%2Fwww.nami.org%2FLearn-More%2FTreatment%2FMental-Health-Medications%2FTardive-Dyskinesia&index=8&md5=9490f0e94728459264815214083cb83d).
| Teva Media Inquiries | TevaCommunicationsNorthAmerica@tevapharm.com (mailto:TevaCommunicationsNorthAmerica@tevapharm.com) |
| Teva Investor Relations Inquiries | TevaIR@Tevapharm.com (mailto:TevaIR@Tevapharm.com) |
